Benefits
Antibody response to seasonal flu vaccination in older adults
In a placebo-controlled trial in 70 adults over 60 living in a nursing home in Japan, 300 mg a day of fucoidan from wakame sporophyll, started 4 weeks before a flu shot, led to higher antibody levels against all three vaccine strains. Antibody levels are a lab marker: flu cases were not counted, and the result has not been repeated.
Natural killer cell activity in healthy adults
In a placebo-controlled pilot in 40 healthy adults, supplied by the maker, 3 g a day of mozuku fucoidan raised natural killer cell activity at 8 weeks versus baseline, but beat placebo only in men. In a small crossover exercise trial, 1 g a day of wakame fucoidan made little difference to most blood immune markers. These are early, marker-level findings.
Prostate health and urinary symptom scores in men
In one 90-day placebo-controlled trial in 95 men aged 45 to 80 with moderate prostate enlargement, 1 g a day of wakame fucoidan lowered a urinary symptom score by about 3.4 points versus 0.9 on placebo. Urine flow, leftover urine and PSA did not differ. The maker funded the study. Urinary symptoms need a medical check first.
Blood sugar and insulin markers
Results are mixed. At 1 g a day for 90 days, insulin resistance did not change in 72 adults with obesity. Other trials found a slower rise in a short-term blood sugar marker in people with prediabetes, a slight HbA1c drop in one subgroup with diet-treated diabetes, and higher insulin with higher insulin resistance in another. No consistent effect yet.
Bowel regularity and gut bacteria balance
In a crossover trial in adults with diet-treated type 2 diabetes, stool frequency rose from about 8 to 9 a week on fucoidan, a before and after change, not a gap versus placebo. A prediabetes trial reported shifts in some gut bacteria versus placebo, and an open-label trial in patients on drug therapy for H. pylori found more beneficial bacteria kept. Small trials of markers, not symptoms in healthy people.
Joint comfort and stiffness
In an open-label pilot in 12 adults with knee osteoarthritis, a seaweed blend (mostly Fucus) with vitamin B6, zinc and manganese lowered a symptom score, more at 1,000 mg than 100 mg a day. But in a placebo-controlled trial in 122 adults with hip or knee osteoarthritis, 300 mg a day of Fucus fucoidan for 12 weeks did no better than placebo.
Mechanism of action
Sulfated sugar chains that differ by source
Fucoidan is a backbone of fucose units carrying sulfate groups, usually with smaller amounts of other sugars. The sulfation pattern, sugar mix and chain length change with species and extraction, which is why fucoidan extracts are not interchangeable and why reproducible, quality-controlled production has been hard.
Limited absorption from the gut
Fucoidan is a large polysaccharide and little of it appears to be absorbed. In a pilot study, a strong anticoagulant effect seen in the test tube was much weaker after 3 g a day by mouth, which the researchers attributed to low intestinal absorption. Much of any effect may therefore start in the gut and its bacteria.
Immune cell signaling (lab and animal work)
In cell and animal studies, fucoidan interacts with macrophages, dendritic cells and natural killer cells and alters cytokine release. These are proposed explanations for the small changes in human immune markers, not mechanisms confirmed in people.
Heparin-like activity in the test tube
Like heparin, sulfated fucoidan lengthens several clotting times in laboratory tests. Taken by mouth the effect is far weaker, but one clotting time did lengthen in a small study, which is why it matters for people on blood thinners.
Clinical trials
Randomized, double-blind, placebo-controlled trial of 300 mg/day mekabu fucoidan (from the sporophyll of Undaria pinnatifida) for 4 weeks before seasonal flu vaccination, continued for 24 weeks in all (Negishi et al. 2013, J Nutr).
70 adults over 60 living in a nursing home in Osaka, Japan. Five died of old age or illness and several others left after hospital stays; the doctors judged none of these related to the product.
The fucoidan group had higher antibody titers than placebo against all three vaccine strains, with the clearest gain against the B strain. Natural killer cell activity only tended to rise (P = 0.08). The trial measured antibodies, not flu illness, and has not been replicated.
Randomized, double-blind, parallel-group, placebo-controlled pilot of 3 g/day Cladosiphon okamuranus (Okinawa mozuku) fucoidan in a drink for 12 weeks; material supplied by the maker, which paid two authors (Tomori et al. 2021, Mar Drugs).
40 healthy Japanese adults (20 fucoidan, 20 placebo), average age about 46.
NK cell activity rose significantly at week 8 compared with baseline in the fucoidan group. Against placebo the difference was significant only in men at week 8. No adverse events were attributed to the drink. A small pilot with a marker outcome.
Randomized, double-blind, placebo-controlled trial of 1 g/day Undaria pinnatifida fucoidan (two 500 mg capsules) for 90 days, funded and supplied by the maker Marinova, whose employees co-authored it (Wimmer et al. 2026, Res Rep Urol).
95 men aged 45 to 80 in India with moderate benign prostatic hyperplasia (symptom score 8 to 19).
The International Prostate Symptom Score fell 3.40 points with fucoidan versus 0.93 with placebo by day 90, with better voiding, storage and quality-of-life scores. Urinary flow rate, residual urine volume and PSA did not differ between groups. Adverse events were similar in number to placebo (12 vs 10). A single sponsor-funded trial.
Single-site, double-blind, placebo-controlled trial of 500 mg fucoidan twice daily for 90 days, funded by the maker Marinova (Wright et al. 2019, J Altern Complement Med).
72 obese adults aged 18 to 65 without diabetes in Tasmania, Australia (35 fucoidan, 37 placebo).
No difference from placebo in the primary outcome, insulin resistance (mean HOMA change 0 on placebo and -0.1 on fucoidan, p = 0.73), or in HbA1c, lipids, weight, waist or blood pressure. The authors list possible reasons, including short duration and low baseline insulin resistance.
Randomized, double-blind, placebo-controlled trial of 1,000 mg/day fucoidan capsules for 12 weeks (Liu et al. 2025, Int J Biol Macromol).
70 Chinese adults with prediabetes.
Glycated serum protein, a short-term blood sugar marker, rose less on fucoidan than on placebo, and TNF-alpha, IL-6 and LPS fell. Stool samples showed more Megamonas and Blautia and less Klebsiella. The authors call the effect on glucose metabolism partial; outcomes were lab markers, not diabetes onset.
Double-blind, randomized, placebo-controlled trial of 300 mg/day Fucus vesiculosus extract (85% fucoidan) for 12 weeks (Myers et al. 2016, Biologics).
122 adults with mild-to-moderate hip or knee osteoarthritis; 96 completed.
Symptom reduction on the Comprehensive Osteoarthritis Test did not differ from placebo. Blood safety tests showed no clinically meaningful changes. This followed a 12-person open-label pilot of a seaweed blend with added nutrients that had reported dose-related improvement.
Single-blind pilot of 3 g/day of 75% fucoidan capsules versus guar gum placebo for 12 days, with clotting tests and test-tube anticoagulant assays (Irhimeh et al. 2009, Blood Coagul Fibrinolysis).
20 adult volunteers (10 fucoidan, 10 placebo).
Activated partial thromboplastin time rose from 28.41 to 34.01 seconds and thrombin time fell slightly. In the test tube fucoidan was a strong anticoagulant, but the authors concluded the effect after swallowing it was not obvious, probably because little is absorbed.